Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label trial of tirzepatide vs semaglutide in type 2 diabetes
2018-004422-29Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change in HbA1c from baseline at 40 weeks (tirzepatide 10 mg and/or 15 mg vs semaglutide 1 mg) and Change in HbA1c from baseline at 40 weeks (tirzepatide 5 mg vs semaglutide 1 mg). Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2018-004422-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004422-29.